In June 2024, a set of eye-catching data from a Chinese medical device at New York Valves 2024, the industry's premier event for interventional cardiac valvular disease, drew widespread attention.
These were the results of a clinical trial of a transcatheter tricuspid valve replacement system - the TRAVEL II study with 6-month follow-up, which was designed to evaluate the safety and efficacy of LuX-Valve Plus in treating patients with severe tricuspid regurgitation.
The results showed that LuX-Valve Plus excelled in both safety and efficacy. Among the safety results, the safety results showed a composite event rate of only 8.33%. Among them, the event rate of cardiac infarction, stroke, use of ECMO (extracorporeal membrane pulmonary oxygenation) or IABP (intra-aortic balloon counterpulsation), acute hepatic failure, prolonged mechanical ventilation (>72 hours), cardiovascular injuries requiring surgical interventions (cardiac perforation, vascular injuries), and life-threatening major hemorrhage was 0. The all-cause mortality rate was only 2.08%, and the event rate of acute renal failure, severe perivalvular leakage, and mid-translational The incidence of surgical tricuspid valve replacement or plasty was 1.04%, 2.08%, and 3.13%, respectively, and the incidence of new-onset degree III atrioventricular block requiring implantation of a permanent pacemaker was only 1.04%.
It is understood that in the past, these patients could only receive traditional conservative medical treatment and conventional surgical treatment with limited results. Data show that surgical treatment of tricuspid regurgitation is unsatisfactory: the perioperative mortality rate for simple surgical tricuspid valve replacement is as high as 10.9%, whereas the perioperative mortality rate for simple surgical tricuspid repair is 8.1%, which is several times higher than the perioperative mortality rate for simple surgical mitral valve repair (1.4%-2.6%), mitral valve replacement (3.8%), and aortic valve replacement (2.2%). perioperative mortality is several times higher than that of simple surgical mitral valve repair (1.4%-2.6%), mitral valve replacement (3.8%) and aortic valve replacement (2.2%).
The introduction of this system offers new hope for such patients with tricuspid regurgitation! Recently, the Medical Professionals Intelligence Center had the honor to meet with Lu Fanglin, Director of the Department of Cardiovascular Surgery at the First People's Hospital of Shanghai Jiao Tong University, one of the main inventors of LuX-Valve Plus, which is the second generation of LuX-Valve, to discuss this innovative product. Discussion.
A forgotten valve, a group of stalwart doctors
LuX-Valve's name is very special, Lu Fanglin explains that it is an acronym combination of Lu and Xu, while Xu refers to Prof. Xu Zhiyun, director of the Department of Thoracic Surgery at the First Affiliated Hospital of the Naval Military Medical University (Shanghai Changhai Hospital).
After graduating from Suzhou Medical College in 1991, Lu was admitted to the Second Military Medical University and stayed at the Department of Thoracic Surgery of Shanghai Changhai Hospital after graduating from his master's degree program in 1996.
Since the 1960s, when Prof. Cai Yuzhi, the founder of the Department of Cardiothoracic Surgery at Shanghai Changhai Hospital, completed China's first prosthetic heart valve replacement surgery, the unit has successively developed the C-L Single (Short) Column Valve and C-L Bi-Leaflet Valve and a series of innovative devices with China's own intellectual property rights. With a series of innovative technologies accumulated over the years, Prof. Xu Zhiyun, director of the Department of Thoracic Surgery at the First Affiliated Hospital of Naval Medical University (Shanghai Changhai Hospital), and his team won the second prize of the 2018 National Science and Technology Progress Award.
In 2015, Prof. Xu Zhiyun led the department to obtain a major special grant from the Ministry of Science and Technology for the research and development of innovative cardiovascular interventional devices. When we were thinking about which direction of interventional device research and development to do, the team put forward the idea of tricuspid valve. At that time, the heart valve science, the left heart valve development is in full swing, while the right heart tricuspid valve valve but no one asked, known as the “forgotten valve”.
There are many reasons for this, but they boil down to two:
First, most of the tricuspid regurgitation is secondary to changes in the course of the disease, symptoms appear later, diuretic treatment can improve the condition, the medical community often do not pay enough attention;
Second, the high mortality rate of simple tricuspid valve surgery has led to a reluctance on the part of both patients and physicians to perform this procedure, which has led to a limited understanding of tricuspid regurgitation in the academic community.
During the research and development process, Prof. Xu Zhiyun's team developed the innovative concepts of “non-radial support dependence” and septal anchoring for tricuspid interventional valve device fixation for the first time in the world.
What are the unique features of these two innovative concepts?
It is well known that the annulus in patients with tricuspid valve insufficiency tends to be large, and if the device is supported, then the valve device must be made very large. Moreover, the tricuspid valve is soft and difficult to fix; there are some important structures around it, such as the right coronary artery trunk, atrioventricular node, coronary sinus, etc. Once the pressure is applied to the relevant tissues, it is easy for conduction block and other conditions to occur and affect the cardiac recovery.The LuX-Valve Plus tricuspid valve is designed to be relatively unique, with a valve stent of about 3cm in the outer rim, a soft skirt and a right atrial disk, respectively, so that the valve is prevented from leakage and does not affect the scar ring. This prevents perivalvular leakage and does not interfere with scar tissue compression. As for the fixation method, it relies on two small “rabbit ears” at the anterior valve site and a tongue-shaped structure that extends into the septum below the septal valve site on the opposite side. The rabbit ears are able to hold the device in place in accordance with the morphology of the tricuspid valve, whereas the tongue is able to fix the septum in place after the position has been determined, thus completing the implantation of the device and avoiding any damage to the surrounding vital organs. This allows the implantation of the device while avoiding compression of the surrounding vital tissues.
The first surgery, an old lady with a complicated condition
After repeated communication with engineers, the first LuX-Valve tricuspid valve was finally designed. in July 2018, the department passed the ethical review and welcomed the first subject in September. It was an old lady in her 70s, who had her mitral mechanical valve replaced more than ten years ago, and then had a pacemaker installed nine years ago. In recent years, she developed severe tricuspid regurgitation, and repeated medication was ineffective, so she should have received surgical intervention, but after evaluation, it was found that the patient's body could no longer tolerate major surgery with extracorporeal circulation, and the team decided to treat her with the LuX-Valve after repeated studies.
The surgery was a success. A team of experts from cardiac surgery, anesthesiology and ultrasound helped the old man solve his tricuspid regurgitation problem. On the same day, there was another tricuspid valve intervention surgery, that was a patient in his 60s, suffering from autoimmune disease and diabetes, after the surgery because of the surgical stress, resulting in skin ulcers in all joint areas, bleeding mouth and throat ulcers caused anemia, we once thought he could not hold out, in the end, surprisingly, he also slowly recovered and improved.
“We also visited her last year, and the elderly are living in good condition.” When talking about the patients who were successfully saved, Lu Fanglin was very happy, “Some of them are very serious patients - such as those with combined laryngeal and ovarian cancers and other malignant tumors, which were considered unsurgical in the past, and the vast majority of them have recovered.”
l A patient with more than ten years of tricuspid regurgitation had a badly swollen calf, and shortly after the operation, he took the initiative to tell Lu Fanglin that previously he had no feeling in his legs at all, and didn't know whether it was hot or cold, but after the operation, he was thrilled to feel that it had all come back.
l A patient said he had tinnitus symptoms after surgery, the original tricuspid valve regurgitation caused by the decline in cardiac output, and now the situation has been reversed, his blood supply was sufficient, the increase in vascular filling in the ear instead of leading to tinnitus, but the good thing is that after a week or two, the patient began to adapt to the tinnitus also disappeared.
l A 70-year-old lady from Shandong, who had a lot of melanin deposits on her calves before the surgery, complained: it's ugly! I didn't dare to wear dresses in summer. After the operation, the melanin began to fade and recover slowly.
“You see, we doctors in the process of communication with patients, patients will pass a lot of news to you, before the tricuspid regurgitation research is very little, followed by the previous severe tricuspid regurgitation is difficult to eliminate, the patient who used this device survived, he will tell you these feelings.” Lu Fanglin lamented, “These are the knowledge that enriches our clinic and may be written in textbooks in the future.”
A British study showed that the prevalence of tricuspid regurgitation in people over the age of 75 is around 4%. “As our country ages, we predict that about 9 million patients may face moderate-to-severe tricuspid regurgitation.” Lu Fanglin pointed out that at present, the medical community has not yet formed a consensus on when to treat tricuspid regurgitation, but wait until the patient has already experienced symptoms and then some of the treatment has been too late to explore a clear therapeutic window has a positive significance.
It is understood that the current generation of products LuX-Valve and the second generation of products LuX-Valve Plus national multi-center confirmatory clinical study has also completed all the enrollment, is preparing to carry out additional research.
In North America and Europe, the LuX-Valve Plus global salvage clinical study has been successfully conducted in the United States, Canada, France, Germany, Spain, Switzerland and other countries, and is continuing to advance the European CE MARK clinical enrollment process. The clinical performance of the device has been recognized by many experts at home and abroad, and with the expansion of the global commercialization of the second-generation product LuX-Valve Plus, more patients with severe tricuspid regurgitation will benefit from it.